arrow
P

Philippe Saïag

Université Paris-Saclay
H指数:56
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic classification of skin adnexal carcinomas: results from a prospective study of 980 patients in the French CARADERM network.

皮肤附属器癌的预后分类:来自法国CARADERM网络一项包含980例患者的前瞻性研究结果。

2026-04-010
PRE
Messages for ultraviolet-radiation protection to fair-skinned populations

关于紫外线防护的信息,面向肤色较浅的人群

2025-11-060
OAAI
Survival outcomes and response to immune checkpoint inhibitors among patients with advanced Merkel cell carcinoma: a retrospective study of 81 patients

晚期 Merkel 细胞癌患者生存结局及对免疫检查点抑制剂的应答:一项包含 81 例患者的回顾性研究

2025-08-020
PRE
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: a nationwide real-life study in France (NEOMEL)

Nardin C,Cavalieri C,Lebbé C,Gérard E,Puyraveau M,Vergara R,等人. 可切除III/IV期黑色素瘤患者的新辅助免疫检查点抑制剂治疗:一项法国全国性真实世界研究(NEOMEL). 英国皮肤病学杂志. (2025) 7:ljaf268. doi: 10.1093/bjd/ljaf268.

2025-07-140
PRE
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study

联合使用encorafenib和binimetinib,随后使用ipilimumab和nivolumab,与直接使用ipilimumab和nivolumab相比,在携带BRAFV600E或BRAFV600K突变的晚期黑色素瘤患者中的疗效比较(EBIN):一项国际、开放标签、随机对照、二期研究

2025-05-280
PRE
Management of Local Skin Reactions Caused by 5-FU 4% Cream for the Treatment of Actinic Keratosis: A Delphi Consensus

5-FU 4%乳膏治疗光线性角化症所致局部皮肤反应的管理:一项德尔菲共识

2025-04-300
OA
An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology

关于欧洲转移性黑色素瘤新型治疗方法可及性的最新进展——2024年欧洲黑色素瘤登记系统与欧洲皮肤肿瘤学会联合调查

2025-02-011
PRE
Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study (vol 73, 102679, 2024)
2025-01-010
OAAI
Methods of nivolumab administration in advanced melanoma: A comparison of patients' clinical outcomes treated with flat dose or weight-adjusted dose, a multicenter observational study
CANCER
IF5.1
2024-12-080
PRE
When to stop immunotherapy for advanced melanoma: the emulated target trials

何时停止晚期黑色素瘤的免疫治疗: 模拟的目标试验

2024-12-010
PRE
The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab plus nivolumab vs. nivolumab in a real-world setting

在真实世界环境中,ipilimumab 联合 nivolumab 与 nivolumab 单药治疗转移性黑色素瘤的一线疗效与安全性比较

2024-11-280
PRE
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study
2024-10-080
OAAI
Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database
2024-09-011
PRE
Operational classification of cutaneous squamous cell carcinomas based on unsupervised clustering of real cases by experts
2024-07-030
OAAI
Real-life ef fi cacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study
2024-07-013
OAAI
Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network
2024-06-120
OAAI
Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them.

皮肤癌是皮肤白皙人群中最常见的癌症,但我们可以预防它们。

2024-06-018
OA